Some authors observed a rapid and sustained clinical response and a concomitant decrease in aPL levels following rituximab administration in patients with steroid-refractory autoimmune hemolytic anemia associated with APS [87]. Here, FASLG is linked to autoimmune polyendocrinopathy.